admin, Author at Integral Molecular

Published by

Integral Molecular Reveals Mechanism Underlying Exquisite Specificity of Claudin 6 Therapeutic Antibody Being Developed for Solid Tumors

PHILADELPHIA–Integral Molecular, the industry leader in antibody discovery for membrane proteins, has published the targeting mechanism enabling best-in-class specificity of its Claudin 6 (CLDN6) […]

Published by

Integral Molecular Partnership: Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors

CTIM-76 named as lead candidate to target Claudin 6 positive cancers IND submission expected in Q1 2024 Context to host webinar on Thursday, December […]

Published by

Integral Molecular Launches New Product Lines of Safe Reporter Viruses for Vaccine Development and Pandemic Preparedness

PHILADELPHIA–Using its extensive experience gained fighting COVID-19 and other virus threats for over 20 years, Integral Molecular has launched an expanded collection of its […]

Published by

Genetic Engineering and Integral Molecular Present – Reporter Virus Tools to Combat Current Viral Threats and the Next Pandemic

Thursday, November 10, 2022 Watch the webinar The COVID-19 pandemic has brought virology to the forefront of many research programs. But how do […]

Published by

Integral Molecular Licenses Claudin 18.2 Monoclonal Antibodies to CARTEXELL for Oncology Cell Therapies

PHILADELPHIA—Integral Molecular, the industry leader in discovering antibodies against complex membrane protein targets, has licensed a panel of monoclonal antibodies (MAbs) to CARTEXELL, enabling […]

Published by

FDA Accepts Integral Molecular’s Letter of Intent (LOI) on Membrane Proteome Array Antibody Specificity Test Into ISTAND Drug Development Tools Pilot Program

PHILADELPHIA—Integral Molecular, the leader in antibody discovery against membrane proteins, has been accepted into the U.S. Food & Drug Administration (FDA)’s ISTAND pilot program. […]

Published by

FDA Announcement: CDER and CBER accept first submission to ISTAND Pilot Program

See statement on FDA website. [9/7/2022] FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have accepted […]

Published by

Genetic Engineering and Integral Molecular Present – Towards IND: Specificity Profiling of Antibody-Based Therapies

Thursday, July 14, 2022 Watch the webinar Rigorous specificity analysis is critical for successful drug development and a safety requirement for monoclonal antibody […]

Published by

Integral Molecular and Optimeos Life Sciences Enter Partnership to Develop mRNA and DNA-Based Gene Therapies Using Molecular Targeting

PHILADELPHIA—Integral Molecular and Optimeos Life Sciences announce a partnership to develop next-generation mRNA and DNA therapeutics that will use antibody-based molecular targeting to direct […]

Author: admin

Integral Molecular Reveals Mechanism Underlying Exquisite Specificity of Claudin 6 Therapeutic Antibody Being Developed for Solid Tumors

Integral Molecular Partnership: Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors

Integral Molecular Launches New Product Lines of Safe Reporter Viruses for Vaccine Development and Pandemic Preparedness

Genetic Engineering and Integral Molecular Present – Reporter Virus Tools to Combat Current Viral Threats and the Next Pandemic

Integral Molecular Licenses Claudin 18.2 Monoclonal Antibodies to CARTEXELL for Oncology Cell Therapies

FDA Accepts Integral Molecular’s Letter of Intent (LOI) on Membrane Proteome Array Antibody Specificity Test Into ISTAND Drug Development Tools Pilot Program

FDA Announcement: CDER and CBER accept first submission to ISTAND Pilot Program

Genetic Engineering and Integral Molecular Present – Towards IND: Specificity Profiling of Antibody-Based Therapies

Integral Molecular and Optimeos Life Sciences Enter Partnership to Develop mRNA and DNA-Based Gene Therapies Using Molecular Targeting

Quick Links

Solutions

Contact Us